EF-CAB3 inhibitors are a class of chemical compounds that target and modulate the activity of EF-CAB3, a protein belonging to the EF-hand calcium-binding protein family. EF-CAB3 plays a significant role in the regulation of intracellular calcium levels, which are crucial for a wide array of cellular processes including signal transduction, muscle contraction, and various enzymatic activities. The EF-hand motif, characteristic of this protein family, is a helix-loop-helix structural domain that coordinates calcium binding. When calcium ions bind to EF-CAB3, the protein undergoes conformational changes that allow it to interact with specific target proteins, thereby initiating or modulating downstream signaling pathways. These pathways are essential for maintaining cellular functions and responding to changes in the cellular environment.
Inhibitors of EF-CAB3 typically function by interfering with the protein's ability to bind calcium or by disrupting its interaction with other proteins. This can be achieved through direct binding to the EF-hand motifs, thereby preventing calcium from binding and blocking the conformational changes necessary for EF-CAB3's activity. Alternatively, these inhibitors might induce structural changes in EF-CAB3 that inhibit its ability to associate with its target proteins, thus modulating the calcium-dependent signaling pathways it regulates. By inhibiting EF-CAB3, these compounds provide researchers with tools to dissect the specific roles of this protein in calcium signaling and to explore its broader implications in cellular physiology. Understanding how EF-CAB3 influences cellular processes through calcium signaling is critical for unraveling the complex network of molecular interactions that govern cell behavior, particularly in contexts where calcium acts as a second messenger to coordinate cellular responses to external and internal stimuli.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can reduce activation of AKT, potentially influencing MAPK pathway activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can modulate protein synthesis and cell growth, impacting MAPK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that can suppress inflammatory responses and MAPK pathway signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can prevent c-Jun phosphorylation, affecting MAPK pathway signaling. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor that prevents ERK phosphorylation and activation within the MAPK pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF inhibitor that can block MEK/ERK signaling, affecting the MAPK pathway. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor with the ability to block MEK1/2 activation and MAPK pathway signaling. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
MEK5 inhibitor that can impede ERK5 activation and signaling in the MAPK pathway. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
MEK inhibitor that can cross the blood-brain barrier, affecting MAPK signaling in the brain. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
ERK inhibitor that can directly inhibit ERK1/2, impacting the MAPK signaling cascade. | ||||||